Key statistics
As of last trade Resmed Inc (RME:DUS) traded at 230.50, -7.80% below its 52-week high of 250.00, set on Aug 25, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 230.50 |
|---|---|
| High | 230.50 |
| Low | 230.50 |
| Bid | 230.50 |
| Offer | 232.80 |
| Previous close | 228.00 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 145.68m |
| Free float | 144.94m |
| P/E (TTM) | 27.28 |
| Market cap | 40.20bn USD |
| EPS (TTM) | 10.12 USD |
| Annual div (ADY) | 2.01 EUR |
|---|---|
| Annual div yield (ADY) | 0.88% |
| Div ex-date | Nov 13 2025 |
| Div pay-date | Dec 18 2025 |
| Next div ex-date | Feb 12 2026 |
| Next div pay-date | Mar 19 2026 |
Data delayed at least 15 minutes, as of Feb 10 2026 07:10 GMT.
More ▼
Announcements
- Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
- Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026
- Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
- Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
- Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026
- Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
- Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
- Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
- Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
- Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
More ▼
